Vitro Receives Approval for Preclinical Diabetes Study Protocol
Complete the form below to unlock access to ALL audio articles.
Vitro Diagnostics, Inc. has announced approval of its preclinical diabetes study protocol. This approval allows the Company to test its stem cell-derived human beta islets for effectiveness in reversing Type I diabetes in experimental models of the disease.
Positive results from such studies could further support various commercial applications of the Company’s stem cell-derived islets that are presently being developed for distribution to select non-therapeutic markets.
Dr. Tinalyn Kupfer, Senior Scientist at Vitro, said, “We are pleased to announce the approval by IACUC. This allows us to move forward with our beta islet testing program to include efforts to reverse diabetes. Together with our on-going functional characterization testing, these new studies will provide information on in-vivo functionality, thus providing important feedback regarding the status of our product. This development is an important component of our program to manufacture stem cell-derived human beta islets that are identical to those present within the pancreas.”
Vitro owns patent-pending technology for the generation and differentiation of adult stem cell lines and has applied this technology to production of beta islets from stem cell lines generated by the Company. Testing to determine reversal of diabetes may open opportunities to proceed with regulatory approval for therapeutic applications.
